Company: SMNR
Filing Date: 2025-08-22
Form Type: DEFA14A
Source: 0001213900-25-079507
Chunk: 30

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-22
Form: DEFA14A
Chunk 30
---
 case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of Denali as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate).

(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Documents, except as specifically disclosed in a subsequent SEC Document filed prior to the date hereof or, with respect to the Closing Date, prior to the Closing Date: (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Denali Material Adverse Effect, (ii) Denali has not incurred any liabilities (contingent or otherwise) other than (A) trade accounts payable and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in Denali’s financial statements pursuant to GAAP or disclosed in filings made with the SEC, (iii) Denali has not altered its method of accounting, (iv) Denali has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) Denali has not issued any equity securities to any officer, director or affiliate. Denali does not have pending before the SEC any request for confidential treatment of information.

<div align='center'>16</div>

(j) Foreign Corrupt Practices. Neither Denali, nor to the Denali’s knowledge, any of its directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the FCPA), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above